查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
HER2 低表达胃或胃食道交界处 (GEJ) 腺癌市场：初步研究 (KOL 见解) - 市场情报 - 流行病学和 2034 年市场预测
市场调查报告书
商品编码
1349828

HER2 低表达胃或胃食道交界处 (GEJ) 腺癌市场：初步研究 (KOL 见解) - 市场情报 - 流行病学和 2034 年市场预测

HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
出版日期: | 出版商: Mellalta Meets LLP | 英文 200 Pages | 商品交期: 5-7个工作天内

价格
简介目录

化疗、免疫疗法和标靶治疗对 HER2 低表达胃或胃食道连接部 (GEJ) 腺癌市场贡献显着。 到 2034 年，新兴疗法的采用预计将成为一个主要转捩点，导致 HER2 低表达胃或胃食道连接处 (GEJ) 腺癌药物市场发生巨大变化。

专家认为，胃癌和其他一些癌症表达 HER2，并对□□ HER2 标靶治疗有反应。 因此，人们对研究 T-DXd 在这些癌症中的应用越来越感兴趣，特别是在 HER2 表达低的患者中。

胃和胃食道连接部 (GEJ) 腺癌是侵袭性恶性肿瘤，治疗选择有限。 HER2 低表达肿瘤定义为免疫组织化学 (IHC) 分析得分为 1+ 或原位杂交 (ISH) 阴性且 IHC 得分为 2+。 这种肿瘤亚型在胃或 GEJ 腺癌中的特征很差，其临床意义尚不清楚。 然而，最近的证据表明 HER2 低表达可能会影响预后并指导治疗决策。

HER2 低表达的胃或胃食道交界部腺癌患者在治疗选择方面面临挑战。 传统的 HER2 标靶疗法，例如曲妥珠单抗，在该亚组中显示出有限的疗效。 因此，应考虑替代治疗策略以改善这些患者的预后。

本报告调查了全球 HER2 低表达胃或胃食道交界处 (GEJ) 腺癌市场，包括市场现状、病例数趋势、患者趋势、竞争产品的市场定位，并为我们提供机会例如

目录

第 1 章执行摘要

第2章 HER2低表达胃或胃食道结合部（GEJ）腺癌的疾病背景

  • HER2 低表达胃或胃食道交界处 (GEJ) 腺癌的定义
  • 原因和症状
  • 病理生理学
  • 导致 HER2 表达低的因素

第 3 章 HER2 低表达胃或胃食道交界处 (GEJ) 腺癌的诊断

第 4 章目前的治疗方法与医疗实务

  • 主要发现
  • 处理演算法

第 5 章未满足的需求

第6章新的治疗方法

  • 主要发现
  • 管道概览
  • HER2 低表达胃或胃食道交界处 (GEJ) 腺癌领域取得显着进展

第 7 章 HER2 低表达胃或胃食道交界处 (GEJ) 腺癌上市时间表和主要市场事件

第 8 章 HER2 低表达胃或胃食道交界处 (GEJ) 腺癌 - 定价与报销

第 9 章 KOL 洞察（美国、欧盟、日本）

第10章未来治疗典范

  • HER2 低表达胃或胃食道交界处 (GEJ) 腺癌的竞争格局和批准
  • 未来的治疗演算法与竞争定位
  • 新疗法的重要数据摘要
  • 当前和未来治疗的年度费用
  • HER2低表达胃或胃食道交界处 (GEJ) 腺癌晚期治疗的策略考虑

第11章市场展望

  • 主要发现
  • 摘要
  • 2034 年之前按国家划分的市场预测

第12章市场促进与约束因子

第13章附录

第14章研究方法

简介目录
Product Code: MM20230025

The HER2-Low Gastric / Gastroesophageal Junction (GEJ) Adenocarcinoma market is hugely contributed by chemotherapy, immunotherapy, and targeted therapies. By 2034, the uptake of novel emerging therapies will serve as a major breakpoint to get a drastic change in the HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma therapeutics market.

"Experts believe that gastric cancer and some other cancers express HER2 and respond to HER2-targeted therapies. This has led to a growing interest in studying the use of T-DXd in these cancers, particularly in patients with low expression of HER2."

Gastric and gastroesophageal junction (GEJ) adenocarcinomas are aggressive malignancies with limited treatment options. HER2-low tumors are defined as having a score of 1+ on immunohistochemical (IHC) analysis or an IHC score of 2+ with negative results on in situ hybridization (ISH). This subset of tumors has not been well characterized in gastric or GEJ adenocarcinomas, and their clinical significance remains unclear. However, recent evidence suggests that HER2-low expression may have prognostic implications and could potentially guide treatment decisions.

Patients with HER2 low gastric or gastroesophageal junction adenocarcinoma pose a challenge in terms of treatment selection. Traditional HER2-targeted therapies, such as trastuzumab, have shown limited efficacy in this subgroup. Therefore, alternative treatment strategies need to be explored to improve outcomes for these patients.

Mellalta's HER2-Low Gastric / Gastroesophageal Junction (GEJ) Adenocarcinoma Report- Market Summary

Report Attributes Details
Market Size 2034: $ billion
Key Market Players: Duality Biologics; AstraZeneca/Daiichi Sankyo
Forecast Period: 2020-2034.
Countries Covered: US, France, Germany, Italy, Spain, UK, China and Japan.
Current SOC Chemotherapy: Immunotherapy; Targeted Therapies.
Future SOC: Targeted Therapies; Combination Approach.
Key Unmet Need: Improved HER2 Assessment; Limited Treatment Option.
Key Clinical Insights: The poor prognosis observed in patients with HER2-low gastric or GEJ adenocarcinoma highlights the need for novel treatment approaches and pharmaceutical companies are now exploring the development of novel agents specifically designed to address the needs of this patient population.
Provider-Patient (PPP) Perspective: Cost-effectiveness of treatment; Better Diagnostic Identification; Access to appropriate treatments and improved options.

Mellalta's HER2-Low Gastric / Gastroesophageal Junction (GEJ) Adenocarcinoma Report - Epidemiology

The total incident cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in the G7 countries are anticipated to increase by a significant number of cases by 2034 for the study period (2020-2034). As per estimates, the United States will present with the highest incidence of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma cases in 2034. Among the EU5, Germany had the highest HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma cases, followed by the UK, France, Italy, and Spain. Japan is reported to have the highest number of treated cases after the United States, Germany, and the UK.

A retrospective study evaluated HER-2 expression in early-stage gastric cancer using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) and found that 8.3% of patients had HER2-positive tumors, 31.8% had HER2-low tumors, and 50.3% had HER2-negative tumors.

Mellalta's HER2-Low Gastric / Gastroesophageal Junction (GEJ) Adenocarcinoma Report - Current Market Size & Forecast Trends

The current standard of care is limited to chemotherapy, immunotherapy, and targeted therapy. Recent developments have shown that ADCs, such as DS-8201 and Disitamab vedotin, release intracellular toxins that can exert a killing effect on neighboring cells without target expression. This bystander effect allows patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma to benefit from HER2-targeted therapy. Therefore, ADCs may expand the population that can benefit from HER2-targeted therapy and are expected to be a novel option for patients whose tumors have low HER2 expression.

The advent of anti-HER2 therapies, such as trastuzumab and trastuzumab deruxtecan (T-DXd), has revolutionized the treatment landscape for HER2-positive gastric or gastroesophageal junction adenocarcinoma. However, the efficacy of these therapies in HER2-low tumors remains uncertain. Recent studies have shown promising results with T-DXd in patients with HER2-low gastric cancer, suggesting that HER2-low tumors may still benefit from HER2-targeted treatments. Based on the results of the DESTINY-Gastric01 trial, T-DXd was approved in Japan for the treatment of patients with HER2-positive unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy. T-DXd is now recommended in the Japanese Gastric Cancer Association treatment guidelines as the third-line treatment for HER2-positive gastric cancer. Additional studies on T-DXd for the treatment of AGC are also ongoing. The DESTINY-Gastric02 trial (NCT04014075) is an open-label, single-arm phase II trial to assess the efficacy and safety of T-DXd in HER2-positive AGC patients who have been treated with previous trastuzumab containing chemotherapy in non-Asian populations. The primary endpoint is the ORR by independent central review, similar to the DESTINY-Gastric01 trial. Seventy-two patients will be enrolled.

Mellalta Meets Current Treatment Strategies in Gastric Cancer

Current Treatment Strategies in Gastric Cancer Source: Daisuke Kotani et al 2021

In the 2024-2034 forecast period, there will be tremendous growth and shift in therapeutic market with the launch of novel emerging therapies like DB-1303 (Duality Biologics), Trastuzumab deruxtecan (AstraZeneca/Daiichi Sankyo), and more. We expect a greater uptake of the new therapies which will result in better treatment outcomes for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma market space. The launch of these upcoming therapies will drive the highly competitive therapeutic market in the coming time.

Questions Answered:

  • What is the size of clinically and commercially relevant drug-treatable HER2 low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma populations, and how will drug-treatment rates of HER2 change over time?
  • Potential challenges and opportunities in implementing targeted therapies for HER2-low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
  • What are the most promising agents in the pipeline, and how will they shape the future of this therapy market?
  • What key drivers and constraints will affect the HER2 low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma therapy market over the forecast period?

Report Highlights:

  • HER2-Low Gastroesophageal Junction (GEJ) Adenocarcinoma - Current Market Trends
  • HER2-Low Gastroesophageal Junction (GEJ) Adenocarcinoma - Current & Forecasted Cases across the G7 Countries
  • HER2-Low Gastroesophageal Junction (GEJ) Adenocarcinoma - Market Opportunities and Sales Potential for Agents
  • HER2-Low Gastroesophageal Junction (GEJ) Adenocarcinoma - Patient-based Market Forecast to 2034
  • HER2-Low Gastroesophageal Junction (GEJ) Adenocarcinoma - Untapped Business Opportunities
  • HER2-Low Gastroesophageal Junction (GEJ) Adenocarcinoma - Product Positioning Vis-a-vis Competitors' Products
  • HER2-Low Gastroesophageal Junction (GEJ) Adenocarcinoma - KOLs Insight

Table of Content

1. Executive Summary

  • 1.1. Key Findings
  • 1.2. Key Market Challenges and Opportunities
  • 1.3. What Do the Experts Say?

2. HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Disease Background

  • 2.1. HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Definition
  • 2.2. Cause & Symptoms
  • 2.3. Pathophysiology
  • 2.4. Factors contributing to the HER2-Low Expression in Breast Cancer

3. HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma-Diagnosis

  • 3.1. HER2 Assessment with Immunohistochemistry (IHC) and In Situ Hybridization (ISH) (ASCO/CAP Guidelines)
  • 3.2. Epidemiology and Patient Populations
  • 3.3. Key Findings
  • 3.4. Methods and data Sources
    • 3.4.1. Country Specific Incident cases of Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (US, Germany, France, Italy, Spain, UK, and Japan)
    • 3.4.2. Country Specific Incident cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
    • 3.4.3. Country Specific Treated cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
    • 3.4.4. Key Sources for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Epidemiology and Model Parameters
      • 3.4.4.1. United States
        • 3.4.4.1.1. United States Incident cases of Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (US, Germany, France, Italy, Spain, UK, and Japan)
        • 3.4.4.1.2. United States Incident cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
        • 3.4.4.1.3. United States Treated cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
      • 3.4.4.2. Germany
        • 3.4.4.2.1. Germany Incident cases of Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (US, Germany, France, Italy, Spain, UK, and Japan)
        • 3.4.4.2.2. Germany Incident cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
        • 3.4.4.2.3. Germany Treated cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
      • 3.4.4.3. France
      • 3.4.4.4. France Incident cases of Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (US, Germany, France, Italy, Spain, UK, and Japan)
      • 3.4.4.5. France Incident cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
      • 3.4.4.6. France Treated cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
    • 3.4.5. Italy
      • 3.4.5.1. Italy Incident cases of Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (US, Germany, France, Italy, Spain, UK, and Japan)
      • 3.4.5.2. Italy Incident cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
      • 3.4.5.3. Italy Treated cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
      • 3.4.5.4. Spain
        • 3.4.5.4.1. Spain Incident cases of Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (US, Germany, France, Italy, Spain, UK, and Japan)
        • 3.4.5.4.2. Spain Incident cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
        • 3.4.5.4.3. Spain Treated cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
      • 3.4.5.5. United Kingdom
        • 3.4.5.5.1. United Kingdom Incident cases of Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (US, Germany, France, Italy, Spain, UK, and Japan)
        • 3.4.5.5.2. United Kingdom Incident cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
        • 3.4.5.5.3. United Kingdom Treated cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
      • 3.4.5.6. Japan
        • 3.4.5.6.1. Japan Incident cases of Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (US, Germany, France, Italy, Spain, UK, and Japan)
        • 3.4.5.6.2. Japan Incident cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
        • 3.4.5.6.3. Japan Treated cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

4. Current Therapy and Medical Practice

  • 4.1. Key Findings
  • 4.2. Treatment Algorithm

5. Unmet Needs

6. Emerging Therapy

  • 6.1. Key Findings
  • 6.2. Pipeline Overview
  • 6.3. Notable Developments in the HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma space
    • 6.3.1. Product Analysis
      • 6.3.1.1. DB-1303 (Duality Biologics)
        • 6.3.1.1.1. Product Profile
        • 6.3.1.1.2. Clinical Development
        • 6.3.1.1.3. Market & Sales Opportunity Forecasted to 2034
      • 6.3.1.2. Trastuzumab deruxtecan (AstraZeneca/Daiichi Sankyo)
        • 6.3.1.2.1. Product Profile
        • 6.3.1.2.2. Clinical Development
        • 6.3.1.2.3. Market & Sales Opportunity Forecasted to 2034
      • 6.3.1.3. Product A (Company A)
        • 6.3.1.3.1. Product Profile
        • 6.3.1.3.2. Clinical Development
        • 6.3.1.3.3. Market & Sales Opportunity Forecasted to 2034
      • 6.3.1.4. Product B (Company B)
        • 6.3.1.4.1. Product Profile
        • 6.3.1.4.2. Clinical Development
        • 6.3.1.4.3. Market & Sales Opportunity Forecasted to 2034
        • 6.3.1.4.4. Others

7. Launch Timeline & Key Market Events for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

8. HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma - Pricing & Reimbursement

9. KOLs Insight (US, EU, JP)

  • 9.1. Unmet Needs
  • 9.2. Analysis of the progresses in terms of approvals & current pipeline;
  • 9.3. Impact on the treatment algorithm and product positioning
  • 9.4. Relevance of new targets/platforms/ therapies Uptake Share %
  • 9.5. Physicians Preferences for the new therapies

10. Future Treatment Paradigm

  • 10.1. HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Competitor Landscape and Approvals Anticipated
  • 10.2. Future Treatment Algorithms and Competitor Positioning
  • 10.3. Key Data Summary for Emerging Treatment
  • 10.4. Annual Cost of Current & Emerging Treatment
  • 10.5. Late Phase Therapy Strategic Considerations in HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

11. Market Outlook

  • 11.1. Key Findings
  • 11.2. Overview
  • 11.3. Country Specific Market Forecast to 2034
    • 11.3.1. Sales of Drugs to Treat HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in the Major Pharmaceutical Markets, 2020-2034
    • 11.3.2. Patient Share of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma by Therapies
    • 11.3.3. Market Forecast by Country
      • 11.3.3.1. United States
        • 11.3.3.1.1. United States Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma 2020-2034 (USD Million)
        • 11.3.3.1.2. United States Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma by Therapy 2020-2034 (USD Million)
      • 11.3.3.2. Germany
        • 11.3.3.2.1. Germany Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma 2020-2034 (USD Million)
        • 11.3.3.2.2. Germany Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma by Therapy 2020-2034 (USD Million)
      • 11.3.3.3. France
        • 11.3.3.3.1. France Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma 2020-2034 (USD Million)
        • 11.3.3.3.2. France Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma by Therapy 2020-2034 (USD Million)
      • 11.3.3.4. Italy
        • 11.3.3.4.1. Italy Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma 2020-2034 (USD Million)
        • 11.3.3.4.2. Italy Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma by Therapy 2020-2034 (USD Million)
      • 11.3.3.5. Spain
        • 11.3.3.5.1. Spain Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma 2020-2034 (USD Million)
        • 11.3.3.5.2. Spain Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma by Therapy 2020-2034 (USD Million)
      • 11.3.3.6. United Kingdom
        • 11.3.3.6.1. United Kingdom Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma 2020-2034 (USD Million)
        • 11.3.3.6.2. United Kingdom Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma by Therapy 2020-2034 (USD Million)
      • 11.3.3.7. Japan
        • 11.3.3.7.1. Japan Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma 2020-2034 (USD Million)
        • 11.3.3.7.2. Japan Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma by Therapy 2020-2034 (USD Million)

12. Market Drivers and Constraints

  • 12.1. What Factors Are Driving the Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma?
  • 12.2. What Factors Are Constraining the Market for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma?

13. Appendix

14. Methodology